Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 172

Sort by

Sort Order Select

Journal Articles

Comprehensive Characteristics and Outcomes of Myeloid Neoplasms Following Chimeric Antigen Receptor T-Cell Therapy for Other Hematologic Malignancies

Blood (2024) 144 (Supplement 1): 1837.

https://doi.org/10.1182/blood-2024-206801

Published: 2024

Journal Articles

Impact of Post-Remission Intensive (IC) Consolidation Chemotherapy Cycles on Overall and Relapse Free Survival after Allogeneic Stem Cell Transplant (SCT) in Patients with Acute Myeloid Leukemia (AML) Receiving IC + Venetoclax

Jennifer Marvin-Peek, Hagop M. Kantarjian, Wei-Ying Jen, Gautam Borthakur, Naval Daver, Abhishek Maiti, Nicholas J. Short, Steven M. Kornblau, Naveen Pemmaraju, Eitan Kugler, Alexandre Bazinet, Yesid Alvarado-Valero, Hussein A. Abbas, Guillermo Garcia-Manero, Uday Popat, Elizabeth J. Shpall, Farhad Ravandi, Courtney D. DiNardo, Tapan M. Kadia

Blood (2024) 144 (Supplement 1): 3572.

https://doi.org/10.1182/blood-2024-202414

Published: 2024

Journal Articles

Fractionated Busulfan, Fludarabine and Thiotepa Myeloablative Conditioning to Improve Transplant Outcomes for Myelofibrosis

Blood (2024) 144 (Supplement 1): 3514.

https://doi.org/10.1182/blood-2024-211371

Published: 2024

Journal Articles

A Phase I Study of Nivolumab in Combination with Ipilimumab for the Treatment of Patients with High Risk or Refractory/Relapsed Acute Myeloid Leukemia Following Allogeneic Stem Cell Transplantation

Blood (2024) 144 (Supplement 1): 1047.

https://doi.org/10.1182/blood-2024-211343

Published: 2024

Journal Articles

Myeloablative Fractionated Busulfan, Fludarabine, Cladribine, Thiotepa and Venetoclax (Cladillac) Conditioning Regimen for Very High-Risk AML/MDS: A Phase 2 Trial

Blood (2024) 144 (Supplement 1): 506.

https://doi.org/10.1182/blood-2024-203338

Published: 2024

Journal Articles

Impact of Donor Age and Donor-Recipient Sex Mismatch on HLA-Matched Related and Unrelated Donor Hematopoietic Cell Transplantation Outcomes

Yosra M. Aljawai, George Chen, Betul Oran, Warren B. Fingrut, Amin M. Alousi, Qaiser Bashir, Chitra Hosing, Partow Kebriaei, David Marin, Uday Popat, Muzaffar H. Qazilbash, Jeremy Ramdial, Portia Smallbone, Katayoun Rezvani, Richard E. Champlin, Elizabeth J. Shpall, Rohtesh S. Mehta

Blood (2024) 144 (Supplement 1): 7441.

https://doi.org/10.1182/blood-2024-210279

Published: 2024

Journal Articles

Improved Outcomes of Haploidentical Hematopoietic Stem Cell Transplantation with Younger Donors

Yosra M. Aljawai, Rima M. Saliba, George Chen, Betul Oran, Warren B. Fingrut, Amin M. Alousi, Qaiser Bashir, Chitra Hosing, Partow Kebriaei, David Marin, Amanda L. Olson, Uday Popat, Muzaffar H. Qazilbash, Jeremy Ramdial, Gabriela Rondon, Portia Smallbone, Samer A. Srour, Richard E. Champlin, Elizabeth J. Shpall

Blood (2024) 144 (Supplement 1): 7442.

https://doi.org/10.1182/blood-2024-210407

Published: 2024

Journal Articles

Impact of Age on Autologous Stem Cell Transplantation Outcomes for AL Amyloidosis

Sophiya S Sami, Qaiser Bashir, Neeraj Y. Saini, Yosra M. Aljawai, Chitra Hosing, Uday Popat, Melody R. Becnel, Gregory P. Kaufman, Sheeba K. Thomas, Donna M. Weber, Robert Z. Orlowski, Richard E. Champlin, Elizabeth J. Shpall, Muzaffar H. Qazilbash, Samer A. Srour

Blood (2024) 144 (Supplement 1): 1923.

https://doi.org/10.1182/blood-2024-211495

Published: 2024

Journal Articles

Predictive Factors for Transplant Outcomes of Cardiac AL Amyloidosis

Abdullah Faisal Deen, Qaiser Bashir, Neeraj Y. Saini, Yosra M. Aljawai, Chitra Hosing, Uday Popat, Melody R. Becnel, Gregory P. Kaufman, Sheeba K. Thomas, Donna M. Weber, Robert Z. Orlowski, Elizabeth J. Shpall, Richard E. Champlin, Muzaffar H. Qazilbash, Samer A. Srour

Blood (2024) 144 (Supplement 1): 1922.

https://doi.org/10.1182/blood-2024-211408

Published: 2024

Journal Articles

Primary Induction Failure Acute Myeloid Leukemia: Immediate Use of Allogeneic Stem Cell Transplantation Vs. Further Induction Chemotherapy

Natalie Rafaeli, Rima M. Saliba, Jayastu Senapati, Naval Daver, Portia Smallbone, Partow Kebriaei, David Marin, Uday Popat, Tapan M. Kadia, Farhad Ravandi, George Chen, Richard E. Champlin, Elizabeth J. Shpall, Betul Oran

Blood (2024) 144 (Supplement 1): 2191.

https://doi.org/10.1182/blood-2024-201718

Published: 2024

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplantation Following CAR T Therapy in Relapsed/Refractory Acute Lymphoblastic Leukemia

Natalie Rafaeli, David Marin, Celina Ledesma, Nitin Jain, Priti Tewari, Issa F. Khouri, Amanda L. Olson, Gheath Alatrash, Nicholas J. Short, Elias Jabbour, Katy Rezvani, Amin M. Alousi, Uday Popat, Richard E. Champlin, Elizabeth J. Shpall, Partow Kebriaei

Blood (2024) 144 (Supplement 1): 2810.

https://doi.org/10.1182/blood-2024-193954

Published: 2024

Journal Articles

Treatment in Clinical Trials Could Potentially Overcome the Disparity in Outcomes of Patients with Acute Myeloid Leukemia from Disadvantaged Neighborhoods

Blood (2024) 144 (Supplement 1): 3817.

https://doi.org/10.1182/blood-2024-210779

Published: 2024

Journal Articles

Updated Results from a Phase II Study of Vibecotamab, a CD3-CD123 Bispecific T-Cell Engaging Antibody, for MDS or CMML after Hypomethylating Failure and in MRD-Positive AML

Blood (2024) 144 (Supplement 1): 1007.

https://doi.org/10.1182/blood-2024-208684

Published: 2024

Journal Articles

TSC-100 and TSC-101 Demonstrate the Potential to Reduce Relapse Rates and Increase Relapse-Free Survival in Patients with AML, ALL, or MDS Undergoing Allogeneic HCT with Reduced Intensity Conditioning (RIC): Preliminary Results from the Phase 1 Alloha Trial

Blood (2024) 144 (Supplement 1): 924.

https://doi.org/10.1182/blood-2024-201526

Published: 2024

Journal Articles

Phase II Clinical Trial of “Off-the-Shelf” NK Cells with Allogeneic Stem Cell Transplantation in Patients with High-Risk Myeloid Malignancies

Jeremy Ramdial, Lorlyn Clemente, Pinaki Banerjee, Bouthaina S. Dabaja, Gheath Al-Atrash, Amin M. Alousi, Betul Oran, Uday Popat, Jin S. Im, Samer A. Srour, George Chen, Partow Kebriaei, Chitra Hosing, David Marin, Katayoun Rezvani, Elizabeth J. Shpall, Richard E. Champlin

Blood (2024) 144 (Supplement 1): 4841.

https://doi.org/10.1182/blood-2024-211389

Published: 2024

Journal Articles

Predictors of Graft-Versus-Host Disease with Post-Transplant Cyclophosphamide

Rima M. Saliba, Yosra M. Aljawai, Amin M. Alousi, Betul Oran, Uday Popat, Richard E. Champlin, Elizabeth J. Shpall

Blood (2024) 144 (Supplement 1): 4890.

https://doi.org/10.1182/blood-2024-210660

Published: 2024

Journal Articles

Long-Term Follow-up of Crenolanib Maintenance after Allogeneic Transplantation in Newly Diagnosed and Relapsed FLT3 Mutated AML

Betul Oran, David Marin, Qaiser Bashir, Sairah Ahmed, Amanda L. Olson, Uday Popat, Partow Kebriaei, Elizabeth J. Shpall, Vinay Jain, Richard E. Champlin

Blood (2024) 144 (Supplement 1): 1497.

https://doi.org/10.1182/blood-2024-207763

Published: 2024

Journal Articles

Large Scale Manufacturing of GMP Grade Cord Blood Derived Megakaryocytes for Chemotherapy Induced Thrombocytopenia

Blood (2024) 144 (Supplement 1): 3926.

https://doi.org/10.1182/blood-2024-209206

Published: 2024

Journal Articles

Blinatumomab maintenance after allogeneic hematopoietic cell transplantation for B-lineage acute lymphoblastic leukemia

Blood (2022) 139 (12): 1908–1919.

https://doi.org/10.1182/blood.2021013290

Published: 2022

Includes: Supplemental data

Journal Articles

Is there an optimal conditioning for older patients with AML receiving allogeneic hematopoietic cell transplantation?

Stefan O. Ciurea, Piyanuch Kongtim, Ankur Varma, Gabriela Rondon, Julianne Chen, Samer Srour, Qaiser Bashir, Amin Alousi, Rohtesh Mehta, Betul Oran, Uday Popat, Chitra Hosing, Amanda Olson, Naval Daver, Marina Konopleva, Richard E. Champlin

Blood (2020) 135 (6): 449–452.

https://doi.org/10.1182/blood.2019003662

Published: 2020

Includes: Supplemental data

NARROW

Comprehensive Characteristics and Outcomes of Myeloid Neoplasms Following Chimeric Antigen Receptor T-Cell Therapy for Other Hematologic Malignancies

Impact of Post-Remission Intensive (IC) Consolidation Chemotherapy Cycles on Overall and Relapse Free Survival after Allogeneic Stem Cell Transplant (SCT) in Patients with Acute Myeloid Leukemia (AML) Receiving IC + Venetoclax

Fractionated Busulfan, Fludarabine and Thiotepa Myeloablative Conditioning to Improve Transplant Outcomes for Myelofibrosis

A Phase I Study of Nivolumab in Combination with Ipilimumab for the Treatment of Patients with High Risk or Refractory/Relapsed Acute Myeloid Leukemia Following Allogeneic Stem Cell Transplantation

Myeloablative Fractionated Busulfan, Fludarabine, Cladribine, Thiotepa and Venetoclax (Cladillac) Conditioning Regimen for Very High-Risk AML/MDS: A Phase 2 Trial

Impact of Donor Age and Donor-Recipient Sex Mismatch on HLA-Matched Related and Unrelated Donor Hematopoietic Cell Transplantation Outcomes

Improved Outcomes of Haploidentical Hematopoietic Stem Cell Transplantation with Younger Donors

Impact of Age on Autologous Stem Cell Transplantation Outcomes for AL Amyloidosis

Predictive Factors for Transplant Outcomes of Cardiac AL Amyloidosis

Primary Induction Failure Acute Myeloid Leukemia: Immediate Use of Allogeneic Stem Cell Transplantation Vs. Further Induction Chemotherapy

Allogeneic Hematopoietic Stem Cell Transplantation Following CAR T Therapy in Relapsed/Refractory Acute Lymphoblastic Leukemia

Treatment in Clinical Trials Could Potentially Overcome the Disparity in Outcomes of Patients with Acute Myeloid Leukemia from Disadvantaged Neighborhoods

Updated Results from a Phase II Study of Vibecotamab, a CD3-CD123 Bispecific T-Cell Engaging Antibody, for MDS or CMML after Hypomethylating Failure and in MRD-Positive AML

TSC-100 and TSC-101 Demonstrate the Potential to Reduce Relapse Rates and Increase Relapse-Free Survival in Patients with AML, ALL, or MDS Undergoing Allogeneic HCT with Reduced Intensity Conditioning (RIC): Preliminary Results from the Phase 1 Alloha Trial

Phase II Clinical Trial of “Off-the-Shelf” NK Cells with Allogeneic Stem Cell Transplantation in Patients with High-Risk Myeloid Malignancies

Predictors of Graft-Versus-Host Disease with Post-Transplant Cyclophosphamide

Long-Term Follow-up of Crenolanib Maintenance after Allogeneic Transplantation in Newly Diagnosed and Relapsed FLT3 Mutated AML

Large Scale Manufacturing of GMP Grade Cord Blood Derived Megakaryocytes for Chemotherapy Induced Thrombocytopenia

Blinatumomab maintenance after allogeneic hematopoietic cell transplantation for B-lineage acute lymphoblastic leukemia

Is there an optimal conditioning for older patients with AML receiving allogeneic hematopoietic cell transplantation?

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only